The multiple acyl-CoA dehydrogenation disorders (MAD) include Episodes of vomiting and altered behaviour, first developing during pregnancy five years earlier, were attributed to severe hyperemesis gravidarum. The symptoms that continued after pregnancy were attributed to migraine. Prophylactic treatment with propranolol, atenolol, verapamil, amitryptiline, phenytoin, carbamazepine, and phenobarbital was ineffective. She had attempted suicide on several occasions.
After recovery from VPA-induced coma she was accusatory, delusional, and sometimes violent towards hospital staff. She complained of frequent headaches and vomited on occasion. Examination of the patient was always normal. Laboratory studies including CBC, platelets, coagulation studies, electrolytes, BUN, creatinine, liver function studies, ESR, and ANA were normal. A lumbar puncture was normal. CT MRI scans of the brain, electromyography, and multiple electroencephalograms were normal. Indeed, clinical observation revealed her seizures to be non-epileptic. Psychiatric evaluation suggested dysthymic disorder (DSM III, Axis I) and a mixed personalilty disorder with borderline and histrionic character traits (DSM III, Axis II). She received counselling and psychotherapy during the next five months without improvement.
Riboflavin (100 mg/day) was administered 21 weeks after coma. The patient's headaches, vomiting, and abnormal behaviour abated within two weeks after starting treatment. She discontinued psychotherapy and became employed for the first time in five years. A voluntary trial off riboflavin at week 61 caused reappearance of her symptoms resulting in hospitalisation. Re-starting riboflavin resulted in prompt clinical improvement. Improvement associated with riboflavin administration has persisted for 15 months. The patient's 5 year old son is clinically normal.
Materials and methods
Urine and plasma samples were obtained within 24 hours after the last VPA dose and at intervals of 1, 7, 21, 23, 24, 34, 62, and 65 weeks after recovery from VPA-induced coma. Samples were stored at -20°C until analysis. Urine creatinine was measured spectrophotometrically. Urinary organic acids were analysed after derivatisation and extraction using a gas chromatograph mass spectrometer with an electron impact ion source (Finnigan-MAT model INCOS 50 GC/MS).' Organic acid excretion was determined as 4mol/mg creatinine relative to the mean and 96th percentile established for 46 patients without metabolic disorders. Carnitine levels were determined by the radioenzymatic method of Brass and Hoppel,4 and urinary acylcarnitine profiles by fast atom bombardment with tandem mass spectrometry. 5 Oxidation of medium and long chain fatty acids by cultured fibroblasts was assessed by measuring the production of 'H20 from [9,10( 
Results Urinary organic acid analysis during the VPA-induced coma showed clearly increased excretion of acetoacetic, lactic, adipic, and ethylmalonic acids (table) . Urinary excretion of 3-hydroxybutyric, 2-ketoglutaric, and suberic acids was moderately elevated. Only the urinary excretion of ethylmalonic acid remained elevated one week after coma. Urinary organic acid analysis was normal at weeks 7,21,23, and 34. When the patient was hospitalised at week 62, however, after discontinuation of riboflavin, organic acid analysis again showed increased excretion of acetoacetic and 2-ketoglutaric acids. Riboflavin therapy was restarted and organic acid analysis was again normal at week 65. The plasma free carnitine level was decreased both during VPA-induced coma and after recovery. Excluding VPAinduced coma, riboflavin administration increased the mean plasma free carnitine level from 22 0 (SEM 2A4) to 35-7 (1-7) umol/hl, (normal 45 (8) 4mol/,ul, n = 3, p < 0-02).
Plasma acylcarnitines were always normal. There was no definite effect of riboflavin administration on the urinary acyl-to-free carnitine ratio; the ratio was increased7 at weeks 0, 7, 21, 23, and 34, and was normal at weeks 62 and 65. The urinary acylcarnitine profile during coma showed acetylcarnitine (the predominant normal urinary acylcarnitine) as well as dicarboxylic acylcarnitines, butyrylcarnitine and glutarylcamitine. Butyrylcarnitine, glutarylcarnitine, and dicarboxylic acylcarnitines were also detected one week after VPA-induced coma, at week 34 during a brief intercurrent illness, and at week 62 while hospitalised after discontinuation of riboflavin (figure). The mean (SEM) oxidation of [9,10( The administration of riboflavin to our patient caused reproducible amelioration of headache, vomiting, and abnormal behaviour and normalisation of the plasma free carnitine level. Riboflavin is the precursor of flavin adenine dinucleotide (FAD), a coenzyme in the transfer of electrons from acyl-CoA dehydrogenases through ETF and ETF-QO. ' The biochemical response to riboflavin we observed is consistent with the stabilisation of a defective ETF or ETF-QO by increased levels of intramitochondrial FAD. As we did not directly assay ETF and ETF-QO activity, we cannot distinguish between primary defects in flavin metabolism, transport, or apoenzyme binding as a cause for acyl-CoA dehydrogenased ysfunction in our patient.' Clinical improvement with riboflavin suggests that this patient's partially compensated metabolic defect was symptomatic. Precipitation of symptoms during pregnancy has also been reported in two other cases of MAD-M presenting in adults.910 A recent study found normal riboflavin levels in pregnant women at delivery." However, a substantial fall in plasma free carnitine with an increase in the acyl-tofree carnitine ratio occurs during pregnancy. '2 As carnitine buffers toxic acyl-CoA metabolites in disorders of beta oxidation through the formation and excretion of acylcarnitines,7 the development of a physiological carnitine insufficiency could explain the onset of symptoms during pregnancy.
Behavioural abnormalities as a primary manifestation of MAD have not been reported previously. Clearly, however, this disorder may affect central nervous system function; seizures and hypotonia are common among infants with MAD:S.' A recent study found biochemical evidence of MAD:M in a young girl with recurrent demyelinating disease mimicking multiple sclerosis.'3 A patient with ETF-deficient MAD:M has recently been described with an extrapyramidal movement disorder and basal ganglia gliosis. '4 The results of the biochemical and fibroblast oxidation studies in our patient suggested a mild acylCoA dehydrogenation disorder. While the clinical presentation may be subtle, we suggest that defective mitochondrial beta oxidation may be a treatable cause of behavioural abnormalities in adults.
